Document Detail

Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies.
MedLine Citation:
PMID:  20595285     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To develop statistical models, based on the analysis of data from phase III randomized placebo-controlled trials of tumor necrosis factor-alpha (TNF-alpha) inhibitors over a 24-week period, that may inform the definition of response measures for clinical trials in psoriatic arthritis (PsA).
METHODS: Data from phase III randomized controlled trials with anti-TNF agents were used. A training set using baseline and 24-week data from 2 trials was used to derive the models, which were then tested on a dataset using baseline and interim data from the third trial, and baseline and interim data from the first 2 trials. Logistic regression, tree analysis, and factor analysis were considered in the development of the models. Receiver-operating characteristic curves were constructed and area under the curve (AUC) calculated to assess performance of the models.
RESULTS: Two models were derived. One was based on differences between baseline and last-visit values, which identified the current 68 tender joint count (TJC68), baseline and change in C-reactive protein (CRP), and the measure with the highest difference among the patient and physician global assessment of disease activity (GDA), patient assessment of pain and the Health Assessment Questionnaire (HAQ). The second model was based on percentage change from baseline and included TJC68, CRP, physician GDA, patient global assessment of arthritis pain, and HAQ. Both models provided high AUC of at least 0.8 for both the training and testing sets.
CONCLUSION: Models for discriminating joint disease response patterns in PsA were derived from data from randomized controlled trials. These models can now be used to inform further consideration of response measures for trials.
Dafna D Gladman; Brian D M Tom; Philip J Mease; Vernon T Farewell
Related Documents :
270465 - The clinical trial in multidisciplinary research.
3398745 - Is there a role for surgery in the acute management of infective endocarditis? a decisi...
2189185 - How much data should we collect in a randomized clinical trial?
6749425 - A case report of data monitoring experience: the nocturnal oxygen therapy trial.
24228275 - Labeling spain with stanford.
21570995 - Estimation of parameters in large offspring number models and ratios of coalescence times.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-07-01
Journal Detail:
Title:  The Journal of rheumatology     Volume:  37     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2011-02-14     Revised Date:  2014-02-19    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1892-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Psoriatic / drug therapy*,  immunology*,  pathology,  physiopathology
Clinical Trials, Phase III as Topic
Health Status
Immunoglobulin G / therapeutic use
Immunosuppressive Agents / therapeutic use*
Models, Statistical*
Placebos / therapeutic use
Randomized Controlled Trials as Topic*
Receptors, Tumor Necrosis Factor / therapeutic use
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Grant Support
MC_U105261167//Medical Research Council
Reg. No./Substance:
0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Placebos; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responde...
Next Document:  Longitudinal analysis of fatigue in psoriatic arthritis.